💊 AI-designed drugs entering clinical trials this year

💊 AI-designed drugs entering clinical trials this year

Alphabet's subsidiary Isomorphic Labs plans to have their first AI-designed drugs in clinical trials before the end of the year. The company focuses on major disease areas including cancer, cardiovascular diseases, and neurodegeneration.

WALL-Y
WALL-Y

Share this story!

  • Alphabet's subsidiary Isomorphic Labs plans to have their first AI-designed drugs in clinical trials before the end of the year.
  • The company focuses on major disease areas including cancer, cardiovascular diseases, and neurodegeneration.
  • Insilico Medicine has already shown positive results from clinical trials with AI-designed drugs for pulmonary fibrosis and inflammatory bowel disease.

Alphabet steps into drug development

Isomorphic Labs, a subsidiary of Alphabet, will test its first AI-designed drugs in clinical trials before the end of the year. This was confirmed by Google DeepMind CEO Demis Hassabis during the World Economic Forum in Davos.

The company, founded in 2021 as a spin-off from DeepMind, uses AI technology to develop new drugs. A central part of their work is AlphaFold, an AI model that can predict the 3D structure of proteins.

In July 2023, Isomorphic Labs initiated collaborations with Eli Lilly and Novartis to use its AI technology in the development of new treatments. The company works with several major disease areas, including cancer, cardiovascular diseases, and neurodegeneration.

Progress in AI-designed drugs

Insilico Medicine became the first in the world to initiate clinical trials of an AI-designed drug in 2023. Their drug INS018_055 was developed to treat idiopathic pulmonary fibrosis, the most common form of pulmonary fibrosis that causes scarring in the lungs.

The company has recently presented positive results from two phase 1 studies of an AI-designed drug for inflammatory bowel disease. Additionally, researchers have used the company's AI platform to identify possible treatments for endometriosis.

Professor James Zou at Stanford University and his team have used generative AI to create structures and chemical recipes for six drugs. According to Zou, there are many potential molecules that could become effective drugs, but have not yet been manufactured or tested.

❤️ Health Tech🧠 Artificial Intelligence

You might also like

WALL-Y 2 min read

💊 New comprehensive study shows over 60 health effects of Ozempic drugs

Study with 215,000 participants shows that Ozempic-like drugs reduce the risk of 42 different health conditions. People taking the medications have a 12% lower risk of developing Alzheimer's disease. The study also shows 9% lower risk of heart attack and 8% lower risk of deep vein thrombosis.

Mathias Sundin 5 min read

🤯 Is Deep Research the biggest thing since ChatGPT?

By applying Deep Research to your information gathering, you become significantly more well-informed and knowledgeable - without it taking more time.

WALL-Y 1 min read

💡 Nobel laureate transforms AI hallucinations into new proteins

David Baker uses AI's ability to generate hallucination to develop entirely new proteins for medical treatment. His team converts AI's imagined protein structures into real proteins that can be used in healthcare. The method has led to 10 million new proteins.